687 related articles for article (PubMed ID: 28814451)
1. Androgen deprivation and immunotherapy for the treatment of prostate cancer.
Gamat M; McNeel DG
Endocr Relat Cancer; 2017 Dec; 24(12):T297-T310. PubMed ID: 28814451
[TBL] [Abstract][Full Text] [Related]
2. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.
Aragon-Ching JB; Williams KM; Gulley JL
Front Biosci; 2007 Sep; 12():4957-71. PubMed ID: 17569623
[TBL] [Abstract][Full Text] [Related]
3. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
4. Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies.
Foley R; Marignol L; Keane JP; Lynch TH; Hollywood D
Prostate; 2011 Apr; 71(5):550-7. PubMed ID: 20945429
[TBL] [Abstract][Full Text] [Related]
5. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
6. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
7. Androgen Receptor Antagonists Suppress Immunotherapy in Prostate Cancer.
Cancer Discov; 2016 Jun; 6(6):569. PubMed ID: 27102077
[TBL] [Abstract][Full Text] [Related]
8. Controversies of androgen ablation therapy for metastatic prostate cancer.
Wilson SS; Crawford ED
Curr Pharm Des; 2006; 12(7):799-805. PubMed ID: 16515496
[TBL] [Abstract][Full Text] [Related]
9. Understanding heterogeneity of treatment effect in prostate cancer.
Aly A; Mullins CD; Hussain A
Curr Opin Oncol; 2015 May; 27(3):209-16. PubMed ID: 25689354
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy for prostate cancer.
Singer EA; Golijanin DJ; Miyamoto H; Messing EM
Expert Opin Pharmacother; 2008 Feb; 9(2):211-28. PubMed ID: 18201145
[TBL] [Abstract][Full Text] [Related]
11. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
12. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
13. Castration-resistant prostate cancer: AUA Guideline.
Cookson MS; Roth BJ; Dahm P; Engstrom C; Freedland SJ; Hussain M; Lin DW; Lowrance WT; Murad MH; Oh WK; Penson DF; Kibel AS
J Urol; 2013 Aug; 190(2):429-38. PubMed ID: 23665272
[TBL] [Abstract][Full Text] [Related]
14. Controversies in the treatment of prostate cancer with maximal androgen deprivation.
McLeod DG; Moul JW
Surg Oncol Clin N Am; 1995 Apr; 4(2):345-59. PubMed ID: 7796290
[TBL] [Abstract][Full Text] [Related]
15. A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer.
Mohamad NV; Soelaiman IN; Chin KY
Endocr Metab Immune Disord Drug Targets; 2017 Nov; 17(4):276-284. PubMed ID: 28925899
[TBL] [Abstract][Full Text] [Related]
16. Tea polyphenol-engineered hybrid cellular nanovesicles for cancer immunotherapy and androgen deprivation therapy.
Guo Y; Wu J; Chen L; Liu L; Bi T; Pan Y; Meng QF; Wang C; Rao L; Li Q
J Nanobiotechnology; 2024 Apr; 22(1):192. PubMed ID: 38637848
[TBL] [Abstract][Full Text] [Related]
17. Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy.
Wong KW; Ma WK; Wong CW; Wong MH; Tsang CF; Tsu HL; Ho KL; Yiu MK
Hong Kong Med J; 2016 Apr; 22(2):106-15. PubMed ID: 26635306
[TBL] [Abstract][Full Text] [Related]
18. Management of the side effects of androgen deprivation therapy in men with prostate cancer.
Flaig TW; Glodé LM
Expert Opin Pharmacother; 2008 Nov; 9(16):2829-41. PubMed ID: 18937615
[TBL] [Abstract][Full Text] [Related]
19. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
Rove KO; Crawford ED
Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
[TBL] [Abstract][Full Text] [Related]
20. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
